Oncotelic Therapeutics, Inc. announced that it has entered into a securities purchase agreement pursuant to which company issued a convertible promissory note to returning investor Mast Hill Fund, L.P., a fund managed by Mast Hill Management, LLC for gross proceeds of $544,500 on May 27, 2022. The note is convertible into shares of the company's common stock, par value $0.01 per share. The principal amount of the note is $605,000.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0375 USD | +4.17% | -3.35% | -2.09% |
1st Jan change | Capi. | |
---|---|---|
-2.09% | 14.39M | |
+7.68% | 113B | |
+10.36% | 106B | |
+0.41% | 22.27B | |
-11.95% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.22% | 17.24B | |
+6.66% | 14.29B | |
+36.23% | 12.52B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. announced that it has received $0.5445 million in funding from Mast Hill Management, LLC